These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 2674984

  • 1. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC, Cummings K.
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC, Gill GM, Cummings KB.
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T, Haukaas S.
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M.
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cancer of the prostate. Treating metastasis with estramustine phosphate.
    Hoeft RT, Jones AG.
    Am J Nurs; 1982 May; 82(5):829-30. PubMed ID: 6918193
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
    Lancina Martín JA, Chantada Abal V, Lamas Meilan AC, González Martín M.
    Actas Urol Esp; 1984 May; 8(5):399-402. PubMed ID: 6524487
    [No Abstract] [Full Text] [Related]

  • 18. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R.
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [Abstract] [Full Text] [Related]

  • 19. Oral estramustine phosphate. Prolonged therapy for advanced carcinoma of prostate.
    Catane R, Mittelman A, Kaufman J, Murphy GP.
    N Y State J Med; 1976 Nov; 76(12):1978-81. PubMed ID: 1069190
    [No Abstract] [Full Text] [Related]

  • 20. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A, Nickel JC.
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.